Zacks Research Issues Negative Estimate for IRWD Earnings

Key Points

• Analysts at Zacks Research have lowered their Q3 2026 earnings per share estimate for Ironwood Pharmaceuticals to $0.12, down from $0.13, maintaining a "Hold" rating on the stock.
• In contrast, Wall Street Zen upgraded Ironwood Pharmaceuticals from a "hold" to a "strong-buy" rating, while the consensus price target remains at $4.94.
• Several large investors have significantly increased their positions in Ironwood Pharmaceuticals, with Marshall Wace LLP notably raising its ownership by 616.3% in the second quarter.

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) - Analysts at Zacks Research dropped their Q3 2026 earnings per share (EPS) estimates for Ironwood Pharmaceuticals in a research note issued to investors on Monday, September 8th. Zacks Research analyst Team now forecasts that the biotechnology company will post earnings per share of $0.12 for the quarter, down from their prior estimate of $0.13. Zacks Research currently has a "Hold" rating on the stock. The consensus estimate for Ironwood Pharmaceuticals' current full-year earnings is $0.10 per share. Zacks Research also issued estimates for Ironwood Pharmaceuticals' Q1 2027 earnings at ($0.02) EPS.

Separately, Wall Street Zen upgraded Ironwood Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Saturday, August 9th. One investment analyst has rated the stock with a Buy rating and six have issued a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $4.94.

Ironwood Pharmaceuticals Stock Up 5.6%

IRWD stock traded up $0.07 during midday trading on Wednesday, reaching $1.31. The stock had a trading volume of 816,432 shares, compared to its average volume of 1,247,972. The business has a fifty day simple moving average of $0.98 and a two-hundred day simple moving average of $0.97. The firm has a market cap of $212.78 million, a price-to-earnings ratio of -26.19 and a beta of 0.33. Ironwood Pharmaceuticals has a twelve month low of $0.53 and a twelve month high of $5.13.

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) last announced its earnings results on Thursday, August 7th. The biotechnology company reported $0.14 earnings per share for the quarter, beating analysts' consensus estimates of ($0.02) by $0.16. Ironwood Pharmaceuticals had a negative return on equity of 2.46% and a negative net margin of 2.25%.The company had revenue of $85.24 million during the quarter, compared to analyst estimates of $62.02 million. Ironwood Pharmaceuticals has set its FY 2025 guidance at EPS.

Hedge Funds Weigh In On Ironwood Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in IRWD. Armistice Capital LLC boosted its holdings in Ironwood Pharmaceuticals by 44.7% during the first quarter. Armistice Capital LLC now owns 13,700,000 shares of the biotechnology company's stock worth $20,139,000 after buying an additional 4,232,000 shares during the last quarter. Millennium Management LLC boosted its holdings in Ironwood Pharmaceuticals by 186.6% during the first quarter. Millennium Management LLC now owns 6,359,682 shares of the biotechnology company's stock worth $9,349,000 after buying an additional 4,140,439 shares during the last quarter. Acadian Asset Management LLC boosted its holdings in Ironwood Pharmaceuticals by 147.6% during the second quarter. Acadian Asset Management LLC now owns 6,549,687 shares of the biotechnology company's stock worth $4,685,000 after buying an additional 3,904,498 shares during the last quarter. AQR Capital Management LLC boosted its holdings in Ironwood Pharmaceuticals by 144.3% during the second quarter. AQR Capital Management LLC now owns 6,165,637 shares of the biotechnology company's stock worth $4,422,000 after buying an additional 3,641,762 shares during the last quarter. Finally, Marshall Wace LLP boosted its holdings in Ironwood Pharmaceuticals by 616.3% during the second quarter. Marshall Wace LLP now owns 3,993,557 shares of the biotechnology company's stock worth $2,875,000 after buying an additional 3,436,036 shares during the last quarter.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.